Stem cells treatment for chronic pain: What can I expect? (Part 3)
https://plus.google.com/+ColumbiaPainManagementPCHoodRiver/ (541) 716-6469 What can I expect if I have stem cell treatment for chronic pain due to arthritis? Doctors at Columbia Pain ...
By: Trey Rigert
See the article here:
Stem cells treatment for chronic pain: What can I expect? (Part 3) - Video
Adult Stem Cells (ASCs), by definition, are unspecialized or undifferentiated cells that not only retain their ability to divide mitotically while still maintaining their undifferentiated state but also, given the right conditions, have the ability to differentiate into different types of cells including cells of different germ-origin an ability referred to as transdifferentiation or plasticity.1,2 In vitro, the conditions under which transdifferentiation occurs can be brought about by modifying the culture medium in which the cells are cultured. In vivo, the same changes are seen when the ASCs are transplanted into a tissue environment different to their own tissue-of origin. Though the exact mechanism of this transdifferentiation of ASCs is still under debate, this ability of ASCs along with their ability to self-renew is of great interest in the field of Regenerative Medicine as a therapeutic tool in being able to regenerate and replace dying, damaged or diseased tissue.
Clinically, however, there are a few criteria that ASCs need to fulfill before they can be viewed as a viable option in Regenerative Medicine. These are as follows:3
Adds Millions of Stem Cells Back into Circulation.
Adipose Tissue Yields an Abundance of ASCs
Compared to any other source, the high concentrations of regenerative cells found in adipose tissue (depots of fat for storing energy) especially in the abdominal region, by sheer volume of availability, ensure an abundance in number of ASCs ranging in the millions per unit volume. The sheer number available also has the added advantage of not needing to be cultured in a laboratory over days in order to get the desired number of ASCs to achieve what is called therapeutic threshold i.e. therapeutic benefit. In addition, harvesting ASCs from adipose tissue through simple, minimally invasive liposuction under local anesthesia is relatively easier and painless and poses minimal risk to the patient compared to all other possible methods.
Adipose tissue ASCs (AT-ASCs) are extremely similar to stem cells isolated from bone marrow (BMSCs). The similarities in profile between the two types of ASCs range from morphology to growth to transcriptional and cell surface phenotypes.4,5 Their similarity extends also to their developmental behavior both in vitro and in vivo. This has led to suggestions that adipose-derived stem cells are in fact a mesenchymal stem cell fraction present within adipose tissue.6
Clinically, however, stromal vascular fraction-derived AT-ASCs have the advantage over their bone marrow-derived counterparts, because of their abundance in numbers eliminating the need for culturing over days to obtain a therapeutically viable number and the ease of the harvest procedure itself being less painful than the harvest of bone marrow. This, in theory, means that an autologous transplant of adipose-derived ASCs will not only work in much the same way as the successes shown using marrow-derived mesenchymal stem cell transplant, but also be of minimal risk to the patient.
AT-ASCs, like BM-ASCs, are called Mesenchymal ASCs because they are both of mesodermal germ-origin. This means that AT-ASCs are able to differentiate into specialized cells of mesodermal origin such as adipocytes, fibroblasts, myocytes, osteocytes and chondrocytes.7,8,9 AT-ASCs are also able (given the right conditions of growth factors) to transdifferentiate into cells of germ-origin other than their own. Animal model and human studies have shown AT-ASCs to undergo cardiomyogenic 10, endothelial (vascular)11, pancreatic (endocrine) 12, neurogenic 13, and hepatic trans-differentiation14 , while also supporting haematopoesis15.
Low Risk to the Patient
Excerpt from:
AdiStem -- Adult Stem Cells Derived from Adipose Tissue ...
Florida Hospital Pepin Heart Institute is First in West & Central Florida to Perform a Groundbreaking Stem Cell Clinical Trial for Heart Failure Patients
The first patient has been treated as part of The ATHENA Trial, which derives stem cells from the patientsown adipose (fat) tissue and injects extracted cells into damaged parts of the heart.
TAMPA, Florida (December 20, 2013) Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute announced the first patient, a 59 year old Clearwater man, has been treated as part of the ATHENA clinical trial. The trial, sponsored by San Diego-based Cytori Therapeutics, derives stem cells from the patients own fat tissue and injects extracted cells into damaged parts of the heart. The ATHENA trial is a treatment for chronic heart failure due to coronary heart disease. Dr. Charles Lambert, Medical Director of Florida Hospital Pepin Heart Institute, is leading the way for the first U.S. FDA approved clinical trial using adipose-derived regenerative cells, known as ADRCs, in chronic heart failure patients. I am pleased to report that all procedures went well. The patient is doing well, he was released and is recovering at home. We look forward to following his progress over the coming months, said Dr. Charles Lambert. Heart failure (HF) can occur when the muscles of the heart become weakened and cannot pump blood sufficiently throughout the body. The injury is most often caused by inadequate blood flow to the heart resulting from chronic or acute cardiovascular disease, including heart attacks. The ATHENA clinical trial procedure is a three step process. First, the trial involves the collection of fat from the patients body by liposuction. Then the fat sample is filtered through a machine that extracts out the stem cells. Finally, the stem cells are injected into the damaged part of the patients heart. During this first case at Florida Hospital Pepin Heart Institute, Dr. Paul Smith performed the liposuction to obtain the fat sample, a team at the Dr. Kiran C. Patel Research Institute isolated stem cells from the fat sample and then Dr. Charles Lambert performed the cell therapy by direct injection into the patients heart. Pepin Heart and Dr. Kiran C. Patel Research Institute is exploring and conducting leading-edge research to develop break-through treatments long before they are even available in other facilities. Stem cells have the unique ability to develop into many different cell types, and in many tissues serve as an internal repair system, dividing essentially without limit to replenish other cells, said Dr. Lambert.
The Pepin Heart Institute has a history of cardiovascular stem cell research as part of the NIH sponsored Cardiac Cell Therapy Research Network (CCTRN) as well as other active cell therapy trials. The trial is a double blind, randomized, placebo controlled study designed to study the use of a patients own Adipose-Derived Regenerative Cells (ADRCs) to treat chronic heart failure from coronary heart disease in patients who are on maximal therapy and still have heart failure symptoms. All trial participants undergo a minor liposuction procedure to remove fat (adipose) tissue. Following the liposuction, trial participants may have their tissue processed with Cytoris proprietary Celution System to separate and concentrate cells, and prepare them for therapeutic use. Trial participants will then have either their own cells or a placebo injected back into their damaged heart tissue. To test whether ADRCs will improve heart function, several measurements will be made, including peak oxygen consumption (VO2max), which measures how much physical exercise (gentle walking on a treadmill) a patient can perform, blood flow to the heart (perfusion), the amount of blood in the left ventricle at the end of contraction and relaxation (end-systolic and end-diastolic volumes), and the fraction of blood that is pumped during each contraction (ejection fraction). After the injection procedure, patients are seen in the clinic for follow-up visits over the first 12 months; they are then contacted by phone once a year for up to five years after the procedure.
There are approximately 5.1 million Americans currently living with heart failure, according to the American Heart Association. Chronic heart failure due to coronary heart disease is a severe, debilitating condition caused by restriction of blood flow to the heart muscle, reducing the hearts oxygen supply and limiting its pumping function. Individuals interested in participating in the ATHENA clinical research trial or learning more can visit http://www.theathenatrial.com or call Brian Nordgren, Florida Hospital Pepin Heart Institute Physician Assistant & Stem Cell Program Lead at (813) 615-7527.
About Florida Hospital Tampa Florida Hospital Tampa is a not-for-profit 475-bed tertiary hospital specializing in cardiovascular medicine, neuroscience, orthopaedics, womens services, pediatrics, oncology, endocrinology, bariatrics, wound healing, sleep medicine and general surgery including minimally invasive and robotic-assisted procedures. Also located at Florida Hospital Tampa is the renowned Florida Hospital Pepin Heart Institute, a recognized leader in cardiovascular disease prevention, diagnosis, treatment and leading-edge research. Part of the Adventist Health System, Florida Hospital is a leading health network comprised of 22 hospitals throughout the state. For more information, visit http://www.FHTampa.org.
About Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute Florida Hospital Pepin Heart Institute is a free-standing cardiovascular institute providing comprehensive cardiovascular care with over 76,000 angioplasty procedures and 11,000 open-heart surgeries in the Tampa Bay region. Leading the way with the first accredited chest pain emergency room in Tampa Bay, the institute is among an elite few in the state of Florida chosen to perform the ground breaking Transcatheter Aortic Valve Replacement (TAVR) procedure. It is also a HeartCaring designated provider and a Larry King Cardiac Foundation Hospital. Florida Hospital Pepin Heart Institute and the Dr. Kiran C. Patel Research Institute, affiliated with the University of South Florida (USF), are exploring and conducting leading-edge research to develop break-through treatments long before they are available in most other hospitals. To learn more, visit http://www.FHPepin.org.
ends
Scoop Media
Here is the original post: Groundbreaking Stem Cell Clinical Trial
Go here to see the original:
florida- StemCell Doctors
A few years ago my mum had a pretty bad diagnosis and whilst investigating every option open to her for treatment I came across the latest research into fat Stem Cell treatments and therapies and I realised that Iwas not looking at the future of medicine any more, I was looking at the present.
Once stem cell treatment had left the breathless headlines of a few years ago Id lost track of the progress being made as it didnt directly my previous specialty. The more I read in the professional, peer reviewed journalsand the more research I came across Ilearned just how far this specialty had progressed to an option that providestangible benefits for a range of conditions and also its power to stave off the negative impact of ageing on the body.
I studied for several years with one of the leading pioneers in thefield andbecame certified for this cutting edge specialty and this led to the opening of MARC stem cell clinic Manila. This really is the most exciting and rewarding work in medicine right now and the opening of our new state of the art clinic means we can bring these procedures to you in the best setting possible. Please feel free to write to me directly if you have any questions.
Read more:
Stem cell clinic Manila
SYDNEY A typical day for Dr. Alex Wawer will find him carefully tracking colourful movements across a computer screen in a small lab in Membertou.
Greg McNeil - Cape Breton Post
From left, Dr. William Harless, Dr. Alex Wawer and Beth Lewis demonstrate the flow citometer at the Encyt Technologies lab in Membertou.
Though the movements of cells as they make their way through the human body might not be of interest to the average person, to the staff at Encyt Technologies it's a fascinating method of differentiating between circulating cancer stem cells and non-cancer stem cells.
"Those are essentially the cells we think are cancer cells, compared to all the other cells of different colours," the research scientist said while pointing at the computer screen.
"Tumour cells would stain these particular (green) ones, compared to the red ones which are probably more like white blood cells."
The resulting implications of such tracking measures could lead to ground-breaking cancer treatment discoveries.
"It's important because stem cells are like the master cells, they are the ones that do everything," said Dr. William Harless, CEO of Encyt Technologies Inc.
"If we can find a way to figure out when they are in the blood, it will help us."
Tracking is more efficient after his lab received it's new flow citometer this week, which was funded by the Cape Breton Regional Hospital Foundation.
Visit link:
Cancer research lab in Membertou welcomes new equipment
FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEsenchymal Stem cell therapy for CAnadian.
By: MSSocietyCanada
The rest is here:
FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video
Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D.
Patricia describes her outcome two years after bone marrow and adipose stem cell therapy for her arthritic knee by Harry Adelson, N.D. http://www.docereclinics.com.
By: Harry Adelson, N.D.
View post:
Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D. - Video
Contact Information
Available for logged-in reporters only
Newswise La Jolla, Calif., February 5, 2015 Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a precise stem cell signaling process that can lead to intestinal tumors if disrupted. The findings add to our understanding of how stem cells give rise to tumors and identify specific stem cell molecules that may be targeted to prevent the onset, progression, and recurrence of intestinal cancers. The results of the study appear online in Cell Reports today.
Accumulating evidence suggests that cancer stem cells are responsible for cancer initiation, progression, metastasis, recurrence, and drug resistance, said Jorge Moscat, Ph.D., program director of the Cell Death and Survival Networks Program at Sanford-Burnham. Our new research provides a better understanding of the signaling cascades that regulate stem cells and is essential for the design of new and more-efficacious therapies for cancer.
We have shown that protein kinase C-zeta (PKC-zeta) normally inhibits stem cell activity through downregulation of two signaling pathways: beta-catenin and Yap, said Maria Diaz-Meco, Ph.D., senior co-author of the paper and professor in the Program. Previously, our lab showed that PKC-zeta acts as a tumor suppressor that maintains homeostasis of intestinal stem cells. The current study reveals the mechanism by which this occurs.
The intestine is covered by a single layer of epithelial cells that are renewed every 3 to 5 days. The pool of cells that replace these epithelial cellsintestinal stem cellsneeds to be regulated to maintain homeostasis.
Disturbing the homeostasis of the stem cell pool can go two waysit can either reduce intestinal epithelial cell regeneration or increase the proliferation of stem cells, said Diaz-Meco. Cancer is produced by the accumulation of mutations in critical genes that control central mechanisms of cell growth. Stem cells are a permanent population in the intestine and a reservoir for those mutations. Therefore, if stem cell activity is increased, as in the case of intestines deficient in PKC-zeta, then the likelihood of developing tumors is much higher, and when the tumor is initiated it becomes more aggressive.
Using a genetically engineered mouse model for intestinal cancer, the research team found that this process is kept under control by direct phosphorylation by PKC-zeta of two essential tumor promoters: beta-catenin and Yap.
Importantly, we confirmed the tumorigenic profiles of PKC-zeta, beta-catenin, and Yap in human colon adenocarcinoma samples. The correlation of human results with our in-vivo mouse studies strongly suggests that Yap and beta-catenin are potential targets of PKC-zeta function and potential targets for new anti-cancer therapies.
"Our results offer new possibilities for the prevention and treatment of intestinal cancers by blocking the pathways that lead to tumors, said Moscat. "They also highlight a new strategy to promote intestinal regeneration after acute or chronic damage, such as that triggered by chemotherapy and radiation.
View post:
New Study Sheds Light on Cancer Stem Cell Regulation
Where:
Angie's Subs, 1436 Beach Blvd., Jacksonville Beach,
Miracle Cures You May Be Missing Revealed at Lifetree Caf A discussion about stem cell therapies will be held at Lifetree Caf on Thursday, February 5, 2015 at 7:00pm. The program, titled Stem Cells: The Miracle Cure You May Be Missing Out On, includes a film featuring a regenerative stem cell procedure as well as an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic. Over the next 20 to 30 years, many drugs we use today will be replaced by stem cells from our own bodies, or cells mass-produced in labs, says Centeno, who notes that the shift in medicine puts at risk much of the $300 billion prescription drug market. Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament, and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate. Admission to the 60-minute event is free. Snacks and beverages are available. Sandwiches can be purchased. Lifetree Caf will be hosted at Angies Subs located at 1436 Beach Boulevard, Jacksonville Beach, FL 32250 (904) 246-2519. Lifetree Caf is a place where people gather for conversation about life and faith in a casual coffeehouse-type setting. Questions about Lifetree may be directed to Donna Lundgren at 904-894-3726or Lundgrens971@gmail.com.
Phone:904-894-3726
Email:Lundgrens971@gmail.com
See the article here:
Open Discussion Conversation Cafe
Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine
If you #39;re tired of treating a chronic injury with prescription drugs, and you #39;ve been told surgery is your next option, there may be a different treatment for you. Dr. Joel Cherdack of...
By: Denver Regenerative Medicine
Read more from the original source:
Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine - Video